These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 10965494)

  • 21. Factors influencing therapeutic efficacy and the host immune response to helper-dependent adenoviral gene therapy in hemophilia A mice.
    Brown BD; Shi CX; Rawle FE; Tinlin S; McKinven A; Hough C; Graham FL; Lillicrap D
    J Thromb Haemost; 2004 Jan; 2(1):111-8. PubMed ID: 14717974
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Helper-dependent adenoviral vectors mediate therapeutic factor VIII expression for several months with minimal accompanying toxicity in a canine model of severe hemophilia A.
    Brown BD; Shi CX; Powell S; Hurlbut D; Graham FL; Lillicrap D
    Blood; 2004 Feb; 103(3):804-10. PubMed ID: 14512318
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antigen-specific tolerance of human alpha1-antitrypsin induced by helper-dependent adenovirus.
    Cerullo V; McCormack W; Seiler M; Mane V; Cela R; Clarke C; Rodgers JR; Lee B
    Hum Gene Ther; 2007 Dec; 18(12):1215-24. PubMed ID: 18021020
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity.
    Schiedner G; Morral N; Parks RJ; Wu Y; Koopmans SC; Langston C; Graham FL; Beaudet AL; Kochanek S
    Nat Genet; 1998 Feb; 18(2):180-3. PubMed ID: 9462752
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Construction and characterization of helper-dependent adenoviral vectors for sustained in vivo gene therapy.
    Oka K; Chan L
    Methods Mol Med; 2005; 108():329-50. PubMed ID: 16028693
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PEGylated helper-dependent adenoviral vector expressing human Apo A-I for gene therapy in LDLR-deficient mice.
    Leggiero E; Astone D; Cerullo V; Lombardo B; Mazzaccara C; Labruna G; Sacchetti L; Salvatore F; Croyle M; Pastore L
    Gene Ther; 2013 Dec; 20(12):1124-30. PubMed ID: 23883962
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expanded-capacity adenoviral vectors--the helper-dependent vectors.
    Morsy MA; Caskey CT
    Mol Med Today; 1999 Jan; 5(1):18-24. PubMed ID: 10088128
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An improved helper-dependent adenoviral vector allows persistent gene expression after intramuscular delivery and overcomes preexisting immunity to adenovirus.
    Maione D; Della Rocca C; Giannetti P; D'Arrigo R; Liberatoscioli L; Franlin LL; Sandig V; Ciliberto G; La Monica N; Savino R
    Proc Natl Acad Sci U S A; 2001 May; 98(11):5986-91. PubMed ID: 11353820
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adenoviral vectors for gene replacement therapy.
    Cao H; Koehler DR; Hu J
    Viral Immunol; 2004; 17(3):327-33. PubMed ID: 15357899
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term stable correction of low-density lipoprotein receptor-deficient mice with a helper-dependent adenoviral vector expressing the very low-density lipoprotein receptor.
    Oka K; Pastore L; Kim IH; Merched A; Nomura S; Lee HJ; Merched-Sauvage M; Arden-Riley C; Lee B; Finegold M; Beaudet A; Chan L
    Circulation; 2001 Mar; 103(9):1274-81. PubMed ID: 11238273
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Helper-dependent adenoviral vectors for liver-directed gene therapy.
    Brunetti-Pierri N; Ng P
    Hum Mol Genet; 2011 Apr; 20(R1):R7-13. PubMed ID: 21470977
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Helper-dependent adenovirus for the gene therapy of proliferative retinopathies: stable gene transfer, regulated gene expression and therapeutic efficacy.
    Lamartina S; Cimino M; Roscilli G; Dammassa E; Lazzaro D; Rota R; Ciliberto G; Toniatti C
    J Gene Med; 2007 Oct; 9(10):862-74. PubMed ID: 17685494
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reduced inflammation and improved airway expression using helper-dependent adenoviral vectors with a K18 promoter.
    Toietta G; Koehler DR; Finegold MJ; Lee B; Hu J; Beaudet AL
    Mol Ther; 2003 May; 7(5 Pt 1):649-58. PubMed ID: 12718908
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Advances in helper-dependent adenoviral vector--a review review].
    Fu Y; He J; Shi C; Hong T
    Wei Sheng Wu Xue Bao; 2009 Feb; 49(2):147-52. PubMed ID: 19445167
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Liver-directed gene therapy with helper-dependent adenoviral vectors: current state of the art and future challenges.
    Vetrini F; Ng P
    Curr Pharm Des; 2011; 17(24):2488-99. PubMed ID: 21774769
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Toxicity and adaptive immune response to intracellular transgenes delivered by helper-dependent vs. first generation adenoviral vectors.
    Mian A; Guenther M; Finegold M; Ng P; Rodgers J; Lee B
    Mol Genet Metab; 2005 Mar; 84(3):278-88. PubMed ID: 15694178
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Production of helper-dependent adenovirus vector relies on helper virus structure and complementing.
    Zhou HS; Zhao T; Rao XM; Beaudet AL
    J Gene Med; 2002; 4(5):498-509. PubMed ID: 12221643
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Cre-expressing cell line and an E1/E2a double-deleted virus for preparation of helper-dependent adenovirus vector.
    Zhou H; Zhao T; Pastore L; Nageh M; Zheng W; Rao XM; Beaudet AL
    Mol Ther; 2001 Apr; 3(4):613-22. PubMed ID: 11319924
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transgene expression up to 7 years in nonhuman primates following hepatic transduction with helper-dependent adenoviral vectors.
    Brunetti-Pierri N; Ng T; Iannitti D; Cioffi W; Stapleton G; Law M; Breinholt J; Palmer D; Grove N; Rice K; Bauer C; Finegold M; Beaudet A; Mullins C; Ng P
    Hum Gene Ther; 2013 Aug; 24(8):761-5. PubMed ID: 23902403
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PEGylated helper-dependent adenoviral vectors: highly efficient vectors with an enhanced safety profile.
    Croyle MA; Le HT; Linse KD; Cerullo V; Toietta G; Beaudet A; Pastore L
    Gene Ther; 2005 Apr; 12(7):579-87. PubMed ID: 15647765
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.